Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EcN + KPS-TPP
- Development stage
- Preclinical
- Lead developer
- Zhimin Jin
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Nanoparticles → Drug Delivery Systems, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
EcN + KPS-TPP (also denoted EcN@KPS-TPP) is a research-stage probiotic delivery system in which the model probiotic bacterium *Escherichia coli* Nissle 1917 (EcN) is encapsulated within keratin nanoparticles coated with tea polyphenols (KPS-TPP). Developed to address the instability of probiotics during gastrointestinal transit, this biologic/nanoparticle-based formulation enhances the acid resistance, intestinal survival, and retention of EcN in the gut. In preclinical studies involving obese mice with induced ulcerative colitis (UC), EcN@KPS-TPP demonstrated the ability to alleviate reactive oxygen species (ROS), reduce inflammatory markers, and modulate the gut microbiota by inhibiting pathogenic bacteria. The formulation is primarily associated with academic research led by Zhimin Jin and targets obesity-related ulcerative colitis.
- Other names
- EcN@KPS-TPPEcN encapsulated within keratin nanoparticles coated with tea polyphenols
Beyond the preview
Go deeper on EcN + KPS-TPP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EcN + KPS-TPP.